Previous 10 | Next 10 |
weisschr/iStock via Getty Images Shares of Prothena ([[PRTA]] -9.6%) are struggling in afternoon trading even though the company earlier today signed a deal with Novo Nordisk ([[NVO]] +0.0%) earlier today potentially worth as much as $1.2B. That agreement calls for Novo to acquire Prothe...
Gainers: Tempest Therapeutics (TPST) +98%, Xtant Medical (XTNT) +31%, Celldex Therapeutics CLDX +29%, SCWorx (WORX) +20%, ReShape Lifesciences (RSLS) +12%.Losers: Sigilon Therapeutics (SGTX) -9%, TransMedics (TMDX) -8%, Prothena PRTA...
Prothena (PRTA) and Novo Nordisk (NVO) have entered into a purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid depos...
Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease AT...
In 2021, energy is where the money is going. Money is flowing out of Momentum stocks this year, and much of it is going into Value names. Commodities are having a strong showing compared to last year. For further details see: If You Want To Know Where The Market Action I...
Prothena has developed broad expertise in removing plaques across different pathologies. FDA's acceptance of amyloid plaque reduction as a sufficient secondary endpoint for an accelerated approval de-risks multiple smallcap biotechs and provides Prothena with a clear regulatory pathwa...
Sven Loeffler/iStock via Getty Images Electric vehicle stocks gain as continued enthusiasm over the potential implications of the infrastructure package bring some buyers back into the sector. Last week's deal between Volvo and Northvolt on EV production and the General Motors-Shell tie-...
Landscape and nature photographer based in Upstate, New York/iStock Editorial via Getty Images Rite Aid could be a “show-me story” in fiscal 2022: Piper Sandler With a ~14.5% loss in share price, Rite Aid (RAD) market cap fell below $1B yesterday in reaction to the mixed perform...
Prothena (PRTA) announces that Bristol Myers Squibb (BMY) has exercised its option under the global neuroscience R&D collaboration to enter into an exclusive U.S. license for PRX005 and will pay Prothena $80M.PRX005 is an investigational anti-tau antibody targeting the microtubule binding...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1 PRX005 is an investigational best-in-class anti-tau antibody targeting the microtubule binding region of tau for the treatment...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...